# Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

> **NCT02063997** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 248 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Arhalofenate 600 mg
- **DRUG:** Allopurinol 300 mg
- **DRUG:** Colchicine 0.6 mg
- **DRUG:** Placebo
- **DRUG:** Arhalofenate 800 mg

## Key facts

- **NCT ID:** NCT02063997
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2018-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02063997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02063997, "Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02063997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*